Overview

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Status:
COMPLETED

Trial end date:
2024-10-28

Target enrollment:

Participant gender:

Summary

68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate cancer, which is needed for clinical trial to be conducted

Phase:

PHASE1

Details

Lead Sponsor:

Norroy Bioscience Co., LTD